Abstract 570P
Background
Osimertinib is the standard of care for the first-line treatment of advanced NSCLC (aNSCLC) patients (pts) with epidermal growth factor receptor (EGFR) activating mutations. Limited Chinese patients’ data in real-world setting are available regarding the effectiveness of osimertinib in EGFRm aNSCLC, especially in patients harboring uncommon EGFR mutations.
Methods
Patients treated with first-line osimertinib were retrospectively collected from 11 hospitals in China between March 25, 2017 and December 31, 2022. Mutations were categorized as EGFR activating mutations (19del/21L858R; cohort 1) and uncommon mutations (G719X, L861Q, S768I, 20ins, de novo T790M; cohort 2). Patient characteristics, progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), and disease control rate (DCR) were analyzed.
Results
A total of 385 patients with stage IV NSCLC were included, 308 pts in cohort 1 and 77 pts in cohort 2. The median age was 59 years, 214 (55.6%) were female, 350 (90.9%) were adenocarcinoma, and 141 (36.6%) patients had documented brain metastases (35 patients received whole-brain radiotherapy). In cohort 1, the median follow-up was 32.8 months and mPFS was 20.8 months (19del subgroup: 22.7 months; 21L858R subgroup: 14.8 months). For patients with/without documented brain metastases, mPFS was 15.6 months and 23.4 months, respectively. mTTP was 21.5 months for all patients. ORR was 75.6%, including 3 patients with CR and 230 patients with PR. DCR was 94.2%. In cohort 2, ORR was 64.9% (50 patients with SD) and DCR was 93.5%. with a median follow-up of 8.3 months, both mPFS and mTTP were 7.3 months. No new safety signals were observed. Table: 570P
| Cohort 1 (19del, 21L858R) | Cohort 2 (G719X, L861Q, S768I, 20ins, de novo T790M) | |
| n (%) | 308 (80%) | 77 (20%) |
| CRPRSDPD | 3 (0.9%)230 (74.7%)57 (18.5%)18 (5.9%) | 0 (0%)50 (64.9%)22 (28.6%)5 (6.5%) |
| ORR (%) | 75.6% | 64.9% |
| DCR (%) | 94.2% | 93.5% |
| mPFS (month) | 20.8m | 7.3m |
| mTTP(month) | 21.5m | 7.3m |
Conclusions
The result is consistent with FLAURA study for patients with EGFR-activating mutation. Osimeritinib showed clinical activity in patients with EGFR uncommon mutations as first-line treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract